Reply to "The perceived efficacy of hydroxychloroquine in observational studies: the results of the confounding effects of 'goals of care'".
作者信息
Dauby Nicolas, Hautekiet Joris, Catteau Lucy, Montourcy Marion, Van Beckhoven Dominique, Bottieau Emmanuel, Goetghebeur Els
机构信息
Department of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium; Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Brussels, Belgium; Environmental Health Research Centre, Public Health School, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium; Cancer Centre, Sciensano, Brussels, Belgium.
出版信息
Int J Antimicrob Agents. 2021 Apr;57(4):106307. doi: 10.1016/j.ijantimicag.2021.106307. Epub 2021 Feb 17.
Abstract
摘要
相似文献
1
Reply to "The perceived efficacy of hydroxychloroquine in observational studies: the results of the confounding effects of 'goals of care'".对《观察性研究中羟氯喹的感知疗效：“治疗目标”的混杂效应结果》的回复
Int J Antimicrob Agents. 2021 Apr;57(4):106307. doi: 10.1016/j.ijantimicag.2021.106307. Epub 2021 Feb 17.
2
Perceived efficacy of hydroxychloroquine in observational studies: Results of the confounding effect of "goals of care".观察性研究中羟氯喹的感知疗效：“治疗目标”混杂效应的结果
Int J Antimicrob Agents. 2021 Apr;57(4):106308. doi: 10.1016/j.ijantimicag.2021.106308. Epub 2021 Feb 17.
3
Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data.羟氯喹治疗需要吸氧的 COVID-19 肺炎患者的临床疗效：利用常规护理数据进行的观察性对比研究。
BMJ. 2020 May 14;369:m1844. doi: 10.1136/bmj.m1844.
4
Bias in observational studies on the effectiveness of in hospital use of hydroxychloroquine in COVID-19.在 COVID-19 住院使用羟氯喹的有效性的观察性研究中存在偏倚。
Pharmacoepidemiol Drug Saf. 2023 Sep;32(9):1001-1011. doi: 10.1002/pds.5632. Epub 2023 Apr 24.
5
Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.羟氯喹或氯喹治疗或预防 COVID-19：一项实时系统评价。
Ann Intern Med. 2020 Aug 18;173(4):287-296. doi: 10.7326/M20-2496. Epub 2020 May 27.
6
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.氯喹或羟氯喹预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2.
7
Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study.羟氯喹在 COVID-19 住院患者中的应用：一项观察性匹配队列研究。
J Glob Antimicrob Resist. 2020 Sep;22:842-844. doi: 10.1016/j.jgar.2020.07.018. Epub 2020 Aug 5.
8
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.羟氯喹联合或不联合阿奇霉素对 COVID-19 患者死亡率的影响：系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Jan;27(1):19-27. doi: 10.1016/j.cmi.2020.08.022. Epub 2020 Aug 26.
9
Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.羟氯喹和托珠单抗治疗 COVID-19 患者：一项观察性研究。
PLoS One. 2020 Aug 13;15(8):e0237693. doi: 10.1371/journal.pone.0237693. eCollection 2020.
10
Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans.药物流行病学、机器学习和 COVID-19：羟氯喹（无论是否联合阿奇霉素）治疗意向分析，及其对住院美国退伍军人 COVID-19 结局的影响。
Am J Epidemiol. 2021 Nov 2;190(11):2405-2419. doi: 10.1093/aje/kwab183.
本文引用的文献
1
The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium.组织特征对比利时入住重症监护病房的COVID-19患者治疗结果的影响。
Lancet Reg Health Eur. 2020 Dec 23;2:100019. doi: 10.1016/j.lanepe.2020.100019. eCollection 2021 Mar.
2
Perceived efficacy of hydroxychloroquine in observational studies: Results of the confounding effect of "goals of care".观察性研究中羟氯喹的感知疗效：“治疗目标”混杂效应的结果
Int J Antimicrob Agents. 2021 Apr;57(4):106308. doi: 10.1016/j.ijantimicag.2021.106308. Epub 2021 Feb 17.
3
Immune determinants of COVID-19 disease presentation and severity.COVID-19 疾病表现和严重程度的免疫决定因素。
Nat Med. 2021 Jan;27(1):28-33. doi: 10.1038/s41591-020-01202-8. Epub 2021 Jan 13.
4
The effect of hydroxychloroquine on platelet activation in model experiments.羟氯喹对模型实验中血小板活化的影响。
J Thromb Thrombolysis. 2021 Aug;52(2):674-679. doi: 10.1007/s11239-020-02325-y. Epub 2021 Jan 2.
5
Reply to 'Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality'.对《低剂量羟氯喹治疗与COVID-19住院患者较低死亡率：关联并不意味着因果关系》的回复
Int J Antimicrob Agents. 2021 Feb;57(2):106261. doi: 10.1016/j.ijantimicag.2020.106261. Epub 2020 Dec 13.
6
Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.低剂量羟氯喹治疗与新冠肺炎住院患者较低死亡率：关联并不意味着因果关系。
Int J Antimicrob Agents. 2021 Jan;57(1):106254. doi: 10.1016/j.ijantimicag.2020.106254. Epub 2020 Nov 28.
7
Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19.COVID-19 住院患者血清中的促血栓形成自身抗体。
Sci Transl Med. 2020 Nov 18;12(570). doi: 10.1126/scitranslmed.abd3876. Epub 2020 Nov 2.
8
The unfinished story of hydroxychloroquine in COVID-19: The right anti-inflammatory dose at the right moment?羟氯喹在新冠病毒肺炎中未完成的故事：在正确的时机使用正确的抗炎剂量？
Int J Infect Dis. 2021 Feb;103:1-2. doi: 10.1016/j.ijid.2020.10.032. Epub 2020 Oct 17.
9
Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants.低剂量羟氯喹治疗对 COVID-19 住院患者死亡率的影响：一项全国性观察研究，纳入 8075 名参与者。
Int J Antimicrob Agents. 2020 Oct;56(4):106144. doi: 10.1016/j.ijantimicag.2020.106144. Epub 2020 Aug 24.
10
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.羟氯喹在非人类灵长类动物中对抗 SARS-CoV-2 感染的应用。
Nature. 2020 Sep;585(7826):584-587. doi: 10.1038/s41586-020-2558-4. Epub 2020 Jul 22.
Zotero 插件